explore -WSS

explore

author：focus 2025-10-01 14:19:19 - browse：2159

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Medical students need to learn the potent medicine of empathy

focus

WSS

Primary care physicians play key roles in Alzheimer's management

Oprah kicked off a national conversation on obesity. Let's have it

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Abortion pill Supreme Court ruling could impact entire drug industry

Ozempic cut risk of death in diabetes patients with chronic kidney disease

The world needs the new pandemic treaty

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

How to save PrEP access — and even expand it

New research sheds light on how often breast cancer is overdiagnosed

Apple is now the first public company to be valued at $3 trillion

States should stop sabotaging methadone treatment reform

The cancer drug shortage isn’t new — and neither are the solutions

Decentralized clinical trials need collaboration to achieve wider use

How to save PrEP access — and even expand it

Lawsuit challenges CMS nursing home minimum staffing rule

hotspot

Medical students need to learn the potent medicine of empathy

Primary care physicians play key roles in Alzheimer's management

Primary care physicians play key roles in Alzheimer's management

Beyond aggravation: Constipation is an American epidemic

Readout Newsletter: Merck, Vertex, and Viking updates

Merck drug for rare lung condition set for approval in U.S.

leisure time

focus

knowledge

leisure time